The U.S. Food and Drug Administration has approved Bizengri for patients with hard-to-treat type of lung and pancreatic cancers. 

The therapy targets the NRG1 gene, which is associated with formation and progression of several tumors. Bizengri is expected to be available to patients in the coming weeks, the company said.

Bizengri is approved for cancer patients whose has disease worsened on or after prior systemic therapy, the FDA said. The recommended dose of the therapy is 750 milligrams as an intravenous infusion every 2 weeks.

The therapy was studied in an early-to-mid-stage trial that enrolled 64 adults with lung cancer and 30 adults with pancreatic adenocarcinoma whose disease worsened following standard-of-care treatment.

The findings showed it can help reduce or destroy the disease in 40% of pancreatic cancer patients and 33% of lung cancer patients.